Advertisement

Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies

      Abstract

      Objectives

      Major advances have recently been made in the treatments of cancer, which now also have the potential to improve patients’ health-related quality of life (HRQOL). We propose the time to HRQOL improvement (TTI) and the time to sustained HRQOL improvement (TTSI) as potentially important cancer outcomes to be used in longitudinal HRQOL analyses.

      Study Design and Setting

      As proof of principle, we defined TTI and TTSI, using the Fine–Gray model to include competing risks in estimates, in a case study in real life of a cohort of newly diagnosed patients with cancer receiving a targeted therapy. HRQOL was evaluated before and during therapy with six assessments over a 24-month period, using the well-validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30.

      Results

      For each assessed HRQOL domain, we assessed TTI and TTSI and estimated the cumulative incidence of patients’ clinically meaningful improvements, also accounting for the occurrence of competing events.

      Conclusion

      TTI and TTSI are potentially important outcomes in the era of modern anticancer therapies. The analysis of TTI and TTSI by competing risks approach will further add to the statistical methods that can be used to inform on the impact of cancer therapies on patients’ HRQOL.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Centers for Disease Control and Prevention
        Health-Related Quality of Life (HRQOL): hrqol Concepts.
        (Available at)
        https://www.cdc.gov/hrqol/concept.htm
        Date accessed: November 5, 2019
        • European Medicine Agency
        Reflection paper on the regulatory guidance for the use of heath related quality of life (HRQL) measures in the evaluation of medicinal product.
        2005 (Available at)
        • Gnanasakthy A.
        • Mordin M.
        • Evans E.
        • Doward L.
        • DeMuro C.
        A review of patient-reported outcome labeling in the United States (2011-2015).
        Value Health. 2017; 20: 420-429
        • Johnson J.R.
        • Temple R.
        Food and Drug Administration requirements for approval of new anticancer drugs.
        Cancer Treat Rep. 1985; 69: 1155-1159
        • Kluetz P.G.
        • O'Connor D.J.
        • Soltys K.
        Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.
        Lancet Oncol. 2018; 19: e267-e274
        • Basch E.
        • Abernethy A.P.
        • Mullins C.D.
        • Reeve B.B.
        • Smith M.L.
        • Coons S.J.
        • et al.
        Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.
        J Clin Oncol. 2012; 30: 4249-4255
        • Mesa R.A.
        • Gotlib J.
        • Gupta V.
        • Catalano J.V.
        • Deininger M.W.
        • Shields A.L.
        • et al.
        Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
        J Clin Oncol. 2013; 31: 1285-1292
        • Deisseroth A.
        • Kaminskas E.
        • Grillo J.
        • Chen W.
        • Saber H.
        • Lu H.L.
        • et al.
        U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
        Clin Cancer Res. 2012; 18: 3212-3217
        • Topp M.S.
        • Zimmerman Z.
        • Cannell P.
        • Dombret H.
        • Maertens J.
        • Stein A.
        • et al.
        Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
        Blood. 2018; 131: 2906-2914
        • Bonnetain F.
        • Dahan L.
        • Maillard E.
        • Ychou M.
        • Mitry E.
        • Hammel P.
        • et al.
        Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
        Eur J Cancer. 2010; 46: 2753-2762
        • Kabbinavar F.F.
        • Wallace J.F.
        • Holmgren E.
        • Yi J.
        • Cella D.
        • Yost K.J.
        • et al.
        Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
        Oncologist. 2008; 13: 1021-1029
        • Charton E.
        • Bachet J.B.
        • Hammel P.
        • Desramé J.
        • Chibaudel B.
        • Cohen R.
        • et al.
        Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: results of the randomized phase II AFUGEM GERCOR clinical trial.
        Cancer Med. 2019; 8: 5079-5088
        • Taphoorn M.J.B.
        • Dirven L.
        • Kanner A.A.
        • Lavy-Shahaf G.
        • Weinberg U.
        • Taillibert S.
        • et al.
        Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial.
        JAMA Oncol. 2018; 4: 495-504
        • Lee C.K.
        • Novello S.
        • Ryden A.
        • Mann H.
        • Mok T.
        Patient-reported symptoms and impact of treatment with Osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial.
        J Clin Oncol. 2018; 36: 1853-1860
        • Chi K.N.
        • Protheroe A.
        • Rodriguez-Antolin A.
        • Facchini G.
        • Suttman H.
        • Matsubara N.
        • et al.
        Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
        Lancet Oncol. 2018; 19: 194-206
        • Charton E.
        • Cuer B.
        • Cottone F.
        • Efficace F.
        • Touraine C.
        • Hamidou Z.
        • et al.
        Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review.
        Qual Life Res. 2020; 29: 867-878
        • Harland S.
        • Staffurth J.
        • Molina A.
        • Hao Y.
        • Gagnon D.D.
        • Sternberg C.N.
        • et al.
        Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
        Eur J Cancer. 2013; 49: 3648-3657
        • Cella D.
        • Grunwald V.
        • Nathan P.
        • Doan J.
        • Dastani H.
        • Taylor F.
        • et al.
        Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2016; 17: 994-1003
        • Cella D.
        • McKendrick J.
        • Kudlac A.
        • Palumbo A.
        • Oukessou A.
        • Vij R.
        • et al.
        Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
        Ann Hematol. 2018; 97: 2455-2463
        • Ludwig H.
        • Ponisch W.
        • Knop S.
        • Egle A.
        • Hinke A.
        • Schreder M.
        • et al.
        Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
        Leuk Lymphoma. 2020; 61: 377-386
        • Ludwig H.
        • Moreau P.
        • Dimopoulos M.A.
        • Mateos M.V.
        • Kaiser M.
        • Hajek R.
        • et al.
        Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
        Blood Cancer J. 2019; 9: 23
        • Reck M.
        • Taylor F.
        • Penrod J.R.
        • DeRosa M.
        • Morrissey L.
        • Dastani H.
        • et al.
        Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study.
        J Thorac Oncol. 2018; 13: 194-204
        • Reck M.
        • Brahmer J.
        • Bennett B.
        • Taylor F.
        • Penrod J.R.
        • DeRosa M.
        • et al.
        Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
        Eur J Cancer. 2018; 102: 23-30
        • Efficace F.
        • Castagnetti F.
        • Martino B.
        • Breccia M.
        • D’Adda M.
        • Angelucci E.
        • et al.
        Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
        Cancer. 2018; 124: 2228-2237
        • Laetsch T.W.
        • Myers G.D.
        • Baruchel A.
        • Dietz A.C.
        • Pulsipher M.A.
        • Bittencourt H.
        • et al.
        Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
        Lancet Oncol. 2019; 20: 1710-1718
        • Cottone F.
        • Anota A.
        • Bonnetain F.
        • Efficace F.
        Time to quality of life improvement as a method for longitudinal analysis of treatment efficacy.
        Qual Life Res. 2017; 26: 37
        • Anota A.
        • Hamidou Z.
        • Paget-Bailly S.
        • Chibaudel B.
        • Bascoul-Mollevi C.
        • Auquier P.
        • et al.
        Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?.
        Qual Life Res. 2015; 24: 5-18
        • Schunemann H.J.
        • Guyatt G.H.
        Commentary--goodbye M(C)ID! Hello MID, where do you come from?.
        Health Serv Res. 2005; 40: 593-597
        • Aaronson N.K.
        • Ahmedzai S.
        • Bergman B.
        • Bullinger M.
        • Cull A.
        • Duez N.J.
        • et al.
        The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
        J Natl Cancer Inst. 1993; 85: 365-376
        • Osoba D.
        • Rodrigues G.
        • Myles J.
        • Zee B.
        • Pater J.
        Interpreting the significance of changes in health-related quality-of-life scores.
        J Clin Oncol. 1998; 16: 139-144
        • Fine J.P.
        • Gray R.J.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509
        • Gray R.J.
        A Class of K-sample tests for comparing the cumulative incidence of a competing risk.
        The Ann Stat. 1988; 16: 1141-1154
        • Putter H.
        • Fiocco M.
        • Geskus R.B.
        Tutorial in biostatistics: competing risks and multi-state models.
        Stat Med. 2007; 26: 2389-2430
        • Austin P.C.
        • Lee D.S.
        • Fine J.P.
        Introduction to the analysis of survival data in the presence of competing risks.
        Circulation. 2016; 133: 601-609
        • Castagnetti F.
        • Breccia M.
        • Gugliotta G.
        • Martino B.
        • D’Adda M.
        • Stagno F.
        • et al.
        Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
        Haematologica. 2016; 101: 1200-1207
        • European Medicine Agency
        ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials.
        2017 (Available at)
        • Lesko C.R.
        • Lau B.
        Bias due to confounders for the exposure-competing risk relationship.
        Epidemiology. 2017; 28: 20-27
        • Matsuyama Y.
        • Yamaguchi T.
        Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methods.
        Pharm Stat. 2008; 7: 202-214
        • Anota A.
        • Barbieri A.
        • Savina M.
        • Pam A.
        • Gourgou-Bourgade S.
        • Bonnetain F.
        • et al.
        Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study.
        Health Qual Life Outcomes. 2014; 12: 192
        • Musoro J.Z.
        • Bottomley A.
        • Coens C.
        • Eggermont A.M.
        • King M.T.
        • Cocks K.
        • et al.
        Interpreting European Organisation for research and treatment for cancer quality of life questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
        Eur J Cancer. 2018; 104: 169-181
        • Maringwa J.T.
        • Quinten C.
        • King M.
        • Ringash J.
        • Osoba D.
        • Coens C.
        • et al.
        Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
        Support Care Cancer. 2011; 19: 1753-1760
        • Kvam A.K.
        • Fayers P.
        • Wisloff F.
        What changes in health-related quality of life matter to multiple myeloma patients? A prospective study.
        Eur J Haematol. 2010; 84: 345-353
        • Musoro J.Z.
        • Coens C.
        • Fiteni F.
        • Katarzyna P.
        • Cardoso F.
        • Russell N.S.
        • et al.
        Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced Breast cancer.
        JNCI Cancer Spectr. 2019; 3: pkz037
        • Fiteni F.
        • Anota A.
        • Bonnetain F.
        • Oster J.P.
        • Pichon E.
        • Wislez M.
        • et al.
        Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
        Eur Respir J. 2016; 48: 861-872